

Prognostic association supports indexing size measures in echocardiography by body surface area

Angus SY Fung^{a,b}, Dhnanjay Soundappan^{a,b}, Daniel E Loewenstein MD^c,
David Playford MBBS PhD^d, Geoffrey Strange PhD^e, Rebecca Kozor MBBS PhD^a,
James Otton MBBS PhD^{b,f}, Martin Ugander MD PhD^{a,b,c,g}

Word count: 2832

^aKolling Institute, Royal North Shore Hospital, and University of Sydney, Sydney, Australia

^bSt Vincent's Clinical School, University of New South Wales, Sydney, Australia

^cDepartment of Clinical Physiology, Karolinska University Hospital, and Karolinska Institutet, Stockholm, Sweden

^dSchool of Medicine, University of Notre Dame, Fremantle, Australia

^eFaculty of Medicine and Health, University of Sydney, Sydney, Australia

^fDepartment of Cardiology, Liverpool Hospital, University of New South Wales, Liverpool, Australia

Email addresses:

Angus SY Fung: angussyfung@gmail.com

Dhnanjay Soundappan: dhnanjay.soundappan@gmail.com

Daniel E Loewenstein: loewenstein.daniel@gmail.com

David Playford: david@playford.biz

Geoffrey Strange: geoff@mozaicsolutions.com.au

Rebecca Kozor: rebeccakozor@gmail.com

James Otton: jotton@gmail.com

Martin Ugander: martin@ugander.com

Funding

This research was supported in part by grants (PI Ugander) from New South Wales Health, Heart Research Australia, and the University of Sydney.

Disclosures

David Playford has received modest honoraria from Alerte Echo IQ. Consultancy fees received from NEDA Limited. No other disclosures from any authors.

Address for correspondence

Professor Martin Ugander MD PhD

Kolling Building, Level 12, Royal North Shore Hospital

St Leonards, Sydney, NSW 2065, Australia

e-mail: martin@ugander.com, tel +61481134220

Abstract and keywords

BACKGROUND: BSA is the most commonly used metric for body size indexation of echocardiographic measures, but its use in patients who are underweight or obese is questioned (BMI < 18.5 kg/m² or ≥ 30 kg/m², respectively).

AIMS: We aim to use survival analysis to identify an optimal body size indexation metric for echocardiographic measures that would be a better predictor of survival than body surface area (BSA) regardless of body mass index (BMI).

METHODS: Adult patients with no prior valve replacement were selected from the National Echocardiography Database Australia. Survival analysis was performed for echocardiographic measures both unindexed and indexed to different body size metrics, with 5-year cardiovascular mortality as the primary endpoint.

RESULTS: Indexation of echocardiographic measures (left ventricular end-diastolic diameter [n=230,109] and mass [n=224,244], left atrial area [n=90,596], aortic sinus diameter [n=90,805], right atrial area [n=59,516], right ventricular diameter [n=3,278], right ventricular outflow tract diameter [n=1,406]) by BSA had better prognostic performance vs unindexed measures (normal weight/overweight: average C-statistic 0.661 vs 0.620; underweight: C-statistic 0.650 vs 0.648; obese: C-statistic 0.627 vs 0.614). Indexation by other body size metrics (lean body mass, height, and/or weight raised to different powers) did not improve prognostic performance versus BSA by a clinically relevant magnitude (average C-statistic increase ≤ 0.02), with smaller differences in other BMI subgroups.

CONCLUSIONS: Indexing measures of cardiac and aortic size by BSA improves prognostic performance regardless of BMI, and no other body size metric has a clinically meaningful better performance.

Keywords: Echocardiography, Indexation

Introduction

Quantification of the dimensions of the heart and great vessels using echocardiography has both diagnostic and prognostic value for the prediction of morbidity and mortality, which also may help guide treatment in patients.¹⁻⁸ Historically, the recommended method for body size indexation of cardiac volumes has been body surface area (BSA).⁹ More recently, recommendations for the indexation of left ventricular mass by an allometric measure of height (raised to the 2.7) have been proposed.^{10, 11} However, there is heterogeneity in the literature as to the best indexation method, and whether or not indexing of cardiac measures improves their predictive value for cardiovascular events.^{6, 12-14} In underweight and overweight patients, correction for BSA can overestimate or underestimate the prevalence of left ventricular hypertrophy, and inaccurately normalise or exaggerate indices of cardiac size.¹² Furthermore, there are concerns regarding the physiological relationships between left ventricular mass and indexation methods. While the relationships between body surface area, height, and weight are non-linear, the indexation of left ventricular mass by these variables often assumes linear relationships.¹⁵ An argument can also be drawn from the theory of similarity, which reasons that relative geometries are best indexed to body size variables of similar dimensionality. For example, since left ventricular mass is related to cardiac dimensions raised to the third power, and BSA is related to a body dimension raised to the second power, it is logical that left ventricular mass should be proportional to $BSA^{3/2}$ (also expressed as $BSA^{1.5}$).¹⁶

Studies on indexation for prognostic performance have been limited in patient sample size and range of cardiac measures indexed.^{5, 17-20} Using the large-scale data available in the National Echocardiography Database of Australia (NEDA), the aim of the study was to derive one or more formulae based on height and weight to provide a method of body size

indexation of cardiac and aortic measures that will be a better predictor of cardiovascular mortality than current methods based on body surface area.

Methods

Study design. NEDA is a large observational registry that includes routinely recorded echocardiographic data across 30 centres in Australia. Individual data linkage is used to incorporate health outcomes such as cardiovascular and all-cause mortality. The study cohort consists of patients over the age of 18 who have typically been referred clinically for imaging evaluation of known or suspected cardiovascular disease. The study was approved by the lead ethics committee at the Royal Prince Alfred Hospital (2019/ETH06989). NEDA is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12617001387314). Ethical approval has been obtained from the Human Research Ethics Committees at the respective recruiting sites, and the study adheres to the Declaration of Helsinki.

Study cohort. Echocardiographic data and basic patient characteristics were collected from participating centres from 1 January 2000 to 21 May 2019, and were transferred into a central database via an automated data extraction process. Echocardiographic measurements were made in accordance with guidelines from the American Society of Echocardiography.⁹ All data was cleaned through the removal of duplicate, inconsistent, and/or impossible measurements, and transformed into a standardized format. Individuals contributing to NEDA were assigned a unique identifier linked to their echocardiograms and their anonymity protected by stringent security protocols. As shown in Figure 1, 631,824 patients were present in the database. Of these, 182,712 (17%) patients were excluded for having less than five years of follow-up time and a further 11,282 (1%) were excluded for prior valve replacement. Echocardiograms with time from echocardiography to census or death, cause of mortality (cardiovascular and all-cause), height, weight, and the cardiac measure of interest

were selected. Different populations were individually filtered for each measure of interest and analysed to maximise the number of patients for analysis. For patients with multiple echocardiograms, the earliest recorded echocardiogram was selected. Patients were grouped according to body mass index (BMI) $<18.5 \text{ kg/m}^2$, BMI $18.5\text{-}30 \text{ kg/m}^2$, or BMI $\geq 30 \text{ kg/m}^2$.

Endpoints. The primary endpoint of interest was cardiovascular mortality. Mortality data was obtained by linkage with the National Death Index.²¹ A detailed probability matching process involving patient identifiers obtained at echocardiographic recording was used to link the survival status of individuals up to the study census date of 21 May 2019. Listed causes of death were described using ICD-10 coding, which allowed for cardiovascular death to be defined (range 100-199 ICD-10AM chapter codes).²²

Statistical analysis. NEDA data analyses and reports were generated in agreement with STROBE guidelines.²³ All data used in analyses were provided and no missing data was imputed. Standard procedures for describing grouped data, such as median [interquartile range (IQR)], and proportions according to patient characteristics were applied.

Cox-proportional hazard models with proportional hazards confirmed by visual inspection and numerical analysis of Schoenfeld residuals were used to derive C-statistics and hazard-ratios (with 95% confidence intervals) for the risk of cardiovascular and all-cause mortality for the entirety of the study follow-up and a five-year follow-up duration. The change in the Akaike information criterion (ΔAIC) was used to interpret the statistical robustness of the body size indexation metrics. Due to the magnification of ΔAIC by large sample sizes, the C-statistic was chosen to dictate the magnitude of difference between metrics and clinical relevance in a sample size independent fashion. Kaplan-Meier curves were constructed to visually inspect differences between indexation measures. An iterative function was coded to derive 50,000 combinations of body size metrics using different height and weight exponents

according to the formula where a given body size metric = $\text{height}^x \cdot \text{weight}^y$. Random combinations of x and y were used as the metric for indexation for the respective echocardiographic measures for subsequent Cox-regression analysis. Cox-regression was performed using the echocardiographic measure indexed by the derived body size metric with five-year cardiovascular mortality as the endpoint to obtain the C-statistic. The C-statistic was color-coded in a scatterplot to present differences in the prognostic strength of different body size metrics including BSA as calculated according to Mosteller²⁴ or Du Bois²⁵, lean body mass formulas by Hume²⁶, Boer²⁷, or James²⁸, BSA raised to various powers, and height and/or weight raised to various powers. All statistical analyses were performed using R 4.0.4 (R Core Team, R Foundation for Statistical Computing, Vienna, Austria).²⁹ Significance was accepted at the level of $p < 0.05$ (two-sided).

Results

Study Cohort. Subject characteristics and size of the study cohorts for various cardiac and aortic measures are presented in Supplementary table 1. Due to the large sample size, differences in baseline characteristics between BMI groups were statistically significant but were not of a clinically meaningful magnitude.

Body size metrics and mortality. Across the echocardiographic measures of right atrial area ($n=59,516$), right ventricular end-diastolic diameter ($n=3,278$), right ventricular outflow tract diameter ($n=1,406$), left atrial area ($n=90,596$), left ventricular end-diastolic diameter ($n=230,109$) and mass ($n=224,244$), and aortic sinus diameter ($n=90,805$), indexation by BSA as calculated by Mosteller had an average C-statistic increase from 0.620 to 0.661 for the normal weight/overweight cohort (average change in Akaike Information Criteria (ΔAIC) 708), an increase from 0.648 to 0.650 for the underweight cohort (ΔAIC 11), and an increase from 0.614 to 0.627 for the obese cohort (ΔAIC 94) compared to unindexed measures for the endpoint of five-year cardiovascular mortality as shown in Table 1.²⁴ Average C-statistics are

provided for composite visualisation of improvements in prognostic value across cardiac measures which followed the same trend. Indexation by other body size metrics (lean body mass, height, and/or weight raised to different powers) yielded a C-statistic increase ≤ 0.02 . Further sex-disaggregated analysis did not differ upon visual inspection, and numerical differences between BSA and the best body size indexation metric were not clinically meaningful (average C-statistic increase ≤ 0.02 , detailed data not shown). Smaller differences in C-statistic between indexation metrics were observed in higher BMI subgroups. Similar results (data not shown) were obtained using long-term cardiovascular mortality not limited to five years, and both long-term and five-year all-cause mortality. Furthermore, similar trends (Supplementary Figure 1-15) were observed across indexation of other aortic dimensions (sinotubular junction, ascending, root, arch) and cardiac chamber volumes (left atrial end-systolic diameter and volume, left ventricular end-diastolic volume). Across all measures, the 95% confidence interval of the C-statistic did not cross 0.50, thus the C-statistic remains significant for the normal weight/overweight group. Indexation by BSA by Mosteller provides an improvement in prognostic performance compared to the unindexed measure. Indexation metrics which have a better prognostic performance than BSA provide only a marginal improvement. However, indexation never negatively impacts prognostic performance. Kaplan-Meier curves (data not shown) did not show visually appreciable differences between indexation by BSA compared to indexation by weight across any measure.

Figure 2 shows how indexation by different body size metrics (based on the formula $\text{height}^x \cdot \text{weight}^y$) perform prognostically, averaged across the representative cardiac and aortic anatomical measure. The color scale shows increasing C-statistics, where each color change represents one percentage point of C-statistic. Numerical values for selected measures are presented in Table 1. In summary, in the normal weight/overweight cohort, indexation by

BSA improves prognostic performance compared to unindexed measures by four percentage points of the C-statistic. Further improvement beyond BSA is limited to <1 percentage point improvement on average. Measures of left ventricular end-diastolic diameter, right ventricular end-diastolic diameter and right ventricular outflow tract diameter were not included in the underweight group due to unreliable C-statistic measure stemming from small sample sizes (n=1385, n=93 and n=38, respectively). Indexation by BSA yielded smaller improvements in prognostic performance in the underweight and obese cohort, but indexation by any other body size metric did not provide any meaningfully stronger association with survival. Further analyses in obese populations and higher BMI subgroups (BMI 30-35, 35-40 and >40) showed that BSA performed similarly to height raised to various powers (data not shown).

Discussion

In this study of body size indexation of cardiac and aortic sizes using real-world echocardiographic data from a large-scale nationwide cohort, indexation by BSA is shown to improve prognostic performance compared to unindexed measures regardless of BMI. Furthermore, no other body size indexation metric provided any meaningful improvement in prognostic performance beyond BSA. The current study comprehensively assessed indexation metrics with varying height and weight exponents in different forms (multiplicative, additive/subtractive, both), and in sex-specific cohorts. It was not possible to derive a body size metric with clinically meaningfully better prognostic performance than BSA. This means that using mortality as the arbiter of indexation effectiveness, no other indexation method exists that is clinically meaningfully better than BSA across all investigated cardiac measures. In accordance with current guidelines for echocardiography⁹, cardiac measures can continue to be indexed using any formula for BSA, regardless of BMI or the echocardiographic measure of interest.

Comparison with indexation by height. The current study found that indexation by BSA improves prognostic performance compared to height regardless of BMI. It has been suggested that indexation by height improves detection of left ventricular hypertrophy and associations with cardiovascular events and mortality compared to BSA in obese populations.^{14, 20, 30} Recently, it has been shown that indexation by height for left atrial volumes was able to maintain proportionality and avoid overcorrection for body size.^{31, 32} However, a consideration of prognostic value is more useful clinically than allometry. While indexation by height, height² and modified versions of BSA have been shown to reclassify patients into binary groups with mortality benefit, cut-off values for these groups are arbitrary and fail to appreciate the continuous nature of such variables.³³ Further, other studies have found no improvement in indexation by height compared to BSA.^{5, 34} The findings of the current study confirm that indexation by height does not provide additional prognostic value compared to indexation by BSA across any BMI group.

Sex differences. The current study found that indexation of cardiac measures disaggregated by sex does not improve prognostic performance. Differences in left ventricular mass have been found between male and female patients.^{35, 36} A consideration of sex in the indexation of cardiac measures measured by cardiac magnetic resonance imaging has been suggested for improved prediction of incident heart failure.¹³ The current study analysed sex-specific cohorts and found that body size metrics derived from sex-specific cohorts were interchangeable with negligible differences in prognostic performance. Thus, the findings of the current study suggest that the relationship between cardiac or aortic size and survival in relation to body size does not fundamentally differ between the sexes. Notably, this is still consistent with using sex-specific cut-offs for normality for a given measure.

Strengths and limitations. The limitations of applying and interpreting big data in NEDA have been acknowledged previously.^{22, 37} At the time of analysis, NEDA did not include

important clinical details of common conditions such as coronary artery disease, ischaemic heart disease, and clinically diagnosed HF, which may impact mortality. Prevalent cardiovascular disease, namely myocardial infarction, can alter the natural relationship between anthropometric parameters and heart structures, and this could not be accounted for in this study.³⁸ That said, the current study used large-scale, real-world data with relevant clinical outcomes that inevitably have measurement variability between centres and observers. While on one hand, this is a limitation as an uncontrolled source of data heterogeneity, it is in fact a strength that reinforces the integrity of observed trends that exist despite sources of variability.

The use of data from NEDA also results in confounding by indication, wherein the inclusion of patients is biased by their need for an echocardiogram. However, this is not a limitation but rather a strength as indexation metrics are intended to be applied to such patients.

The main endpoint of consideration, cardiovascular mortality, was linked from the Australian National Death Index which has a high sensitivity and specificity (93% and 90%, respectively) validating its use as the primary endpoint.²¹ Furthermore, in the current study, similar trends were also observed across all-cause mortality, further reinforcing the validity of the results.

The current study did not include the impact of age on aortic size or mortality which may be a source of uncontrolled confounding. An increase in age has long been established to be related to an increased aortic size, which would affect interpretation of the indexed measure.^{39, 40} The association between age and mortality is both intuitive and widely accepted.^{41, 42} However, a consideration of age in choice of body size indexation metric is impractical clinically, and fails to achieve the goal of indexation, namely, to account for body size. Given the strong association of age with mortality, the inclusion of age into statistical models overcasts differences between indexation metrics. A consideration of age is more

appropriate for cut-off values of the indexed cardiac and aortic size measure, but not necessarily for the choice of body size indexation metric. Importantly, similar age distributions existed between the respective cohorts in the current study. Thus, while theoretically attractive, consideration of the effect of age does not contribute to addressing the purpose of the optimal choice of body size indexation method.

The NEDA cohort comprises patients being investigated for known or suspected cardiovascular disease. Data was largely obtained from specialist centres or clinics in Australia. While the NEDA cohort is representative of the diverse and multiethnic population in Australia with a largely high-functioning level of health care, applicability may be different in other contexts.

The current study has definitively demonstrated that measures of cardiac and aortic size should continue to be indexed by BSA regardless of BMI. No other existing or derived body size metric (lean body mass or height and/or weight raised to various powers) is clinically meaningfully better. Left atrial size and left ventricular mass indexed to BSA provided the strongest prognostic association of all transthoracic echocardiographic size measures.

Acknowledgements

The authors gratefully acknowledge the NEDA organisation and its contributing sites and investigators for the creation of the NEDA database.

References

1. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. *Ann. Intern. Med.* 1986;105(2):173-8.
2. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Bartocchini C, et al. Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass. *J. Am. Coll. Cardiol.* 1995;25(4):871-8.
3. Krumholz HM, Larson M, Levy D. Prognosis of left ventricular geometric patterns in the Framingham Heart Study. *J. Am. Coll. Cardiol.* 1995;25(4):879-84.
4. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. *Ann. Intern. Med.* 1991;114(5):345-52.
5. Ristow B, Ali S, Na B, Turakhia MP, Whooley MA, Schiller NB. Predicting heart failure hospitalization and mortality by quantitative echocardiography: is body surface area the indexing method of choice? *The Heart and Soul Study. J. Am. Soc. Echocardiogr.* 2010;23(4):406-13.
6. Liao Y, Cooper RS, Durazo-Arvizu R, Mensah GA, Ghali JK. Prediction of mortality risk by different methods of indexing for left ventricular mass. *J. Am. Coll. Cardiol.* 1997;29(3):641-7.
7. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. *N. Engl. J. Med.* 1990;322(22):1561-6.

8. Benjamin EJ, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death: the Framingham Heart Study. *Circulation*. 1995;92(4):835-41.
9. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European association of Cardiovascular Imaging. *Eur. Heart J. Cardiovasc. Imaging*. 2015;16(3):233-71.
10. Perrone-Filardi P, Coca A, Galderisi M, Paolillo S, Alpendurada F, de Simone G, et al. Non-invasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus paper from the European Association of Cardiovascular Imaging (EACVI), the European Society of Cardiology Council on Hypertension, and the European Society of Hypertension (ESH). *European Heart Journal-Cardiovascular Imaging*. 2017;18(9):945-60.
11. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *European heart journal*. 2018;39(33):3021-104.
12. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. *Eur. Heart. J. Cardiovasc. Imaging*. 2006;7(2):79-108.
13. Bluemke DA, Kronmal RA, Lima JA, Liu K, Olson J, Burke GL, et al. The relationship of left ventricular mass and geometry to incident cardiovascular events:

- the MESA (Multi-Ethnic Study of Atherosclerosis) study. *J. Am. Coll. Cardiol.* 2008;52(25):2148-55.
14. Chirinos JA, Segers P, De Buyzere ML, Kronmal RA, Raja MW, De Bacquer D, et al. Left ventricular mass: allometric scaling, normative values, effect of obesity, and prognostic performance. *Hypertension.* 2010;56(1):91-8.
 15. De Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. *J. Am. Coll. Cardiol.* 1992;20(5):1251-60.
 16. Dewey FE, Rosenthal D, Murphy Jr DJ, Froelicher VF, Ashley EA. Does size matter? Clinical applications of scaling cardiac size and function for body size. *Circulation.* 2008;117(17):2279-87.
 17. Devereux RB, Lutas EM, Casale PN, Kligfield P, Eisenberg RR, Hammond IW, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. *J. Am. Coll. Cardiol.* 1984;4(6):1222-30.
 18. Airale L, Paini A, Ianniello E, Mancusi C, Moreo A, Vaudo G, et al. Left atrial volume indexed for height² is a new sensitive marker for subclinical cardiac organ damage in female hypertensive patients. *Hypertens. Res.* 2021:1-8.
 19. Cuspidi C, Carugo S, Tadic M. Looking at the best indexing method of left atrial volume in the hypertensive setting. *Hypertens. Res.* 2021:1-3.
 20. De Simone G, Kizer JR, Chinali M, Roman MJ, Bella JN, Best LG, et al. Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Study. *Am. J. Hypertens.* 2005;18(2):191-6.
 21. Magliano D, Liew D, Pater H, Kirby A, Hunt D, Simes J, et al. Accuracy of the Australian National Death Index: comparison with adjudicated fatal outcomes among

- Australian participants in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study. Australian and New Zealand journal of public health. 2003;27(6):649-53.
22. Playford D, Strange G, Celermajer DS, Evans G, Scalia GM, Stewart S, et al. Diastolic dysfunction and mortality in 436 360 men and women: the National Echo Database Australia (NEDA). Eur. Heart J. Cardiovasc. Imaging. 2021;22(5):505-15.
 23. Sharp MK, Tokalić R, Gómez G, Wager E, Altman DG, Hren D. A cross-sectional bibliometric study showed suboptimal journal endorsement rates of STROBE and its extensions. Journal of clinical epidemiology. 2019;107:42-50.
 24. Mosteller R. Simplified calculation of body-surface area. N. Engl. J. Med. 1987;317(17):1098-.
 25. DuBois D. A formula to estimate the approximate surface area if height and body mass be known. Arch intern med. 1916;17:863-71.
 26. Hume R. Prediction of lean body mass from height and weight. Journal of clinical pathology. 1966;19(4):389-91.
 27. Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am. J. Physiol. Renal Physiol. 1984;247(4):F632-F6.
 28. Research DMGoO, James WPT, Waterlow JC. Research on Obesity: a Report of the DHSS/MRC Group; Compiled by WPT James: HM Stationery Office; 1976.
 29. Team RC 2013;Pages. Accessed at R Foundation for Statistical Computing at <http://www.r-project.org/>.
 30. De Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension. 1994;23(5):600-6.

31. Jeyaprakash P, Moussad A, Pathan S, Sivapathan S, Ellenberger K, Madronio C, et al. A Systematic Review of Scaling Left Atrial Size: Are Alternative Indexation Methods Required for an Increasingly Obese Population? *J Am Soc Echocardiogr.* 2021;34(10):1067-76.e3.
32. Moukarzel J, Guevara E, Casciaro ME, Guilenea FN, Pascaner AF, Craiem D. Echocardiographic Measurements of Left Heart Chamber Size in a Large Cohort of Subjects: Comparison of Body Surface Area and Height Indexing to Account for Effects of Obesity. *Journal of the American Society of Echocardiography.* 2022;35(11):1159-67. e2.
33. Davis EF, Crousillat DR, He W, Andrews CT, Hung JW, Danik JS. Indexing Left Atrial Volumes. *JACC: Cardiovascular Imaging.* 2022;15(6):989-97.
34. Simone Gd, Devereux RB, Maggioni AP, Gorini M, Divitiis Od, Verdecchia P. Different normalizations for body size and population attributable risk of left ventricular hypertrophy: the MAVI study. *American journal of hypertension.* 2005;18(10):1288-93.
35. Hammond IW, Devereux RB, Alderman MH, Laragh JH. Relation of blood pressure and body build to left ventricular mass in normotensive and hypertensive employed adults. *J. Am. Coll. Cardiol.* 1988;12(4):996-1004.
36. Liebson PR, Grandits G, Prineas R, Dianzumba S, Flack JM, Cutler JA, et al. Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). *Circulation.* 1993;87(2):476-86.
37. Strange G, Stewart S, Celermajer D, Prior D, Scalia GM, Marwick T, et al. Poor long-term survival in patients with moderate aortic stenosis. *J. Am. Coll. Cardiol.* 2019;74(15):1851-63.

38. Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. *Cardiovascular research*. 2009;81(3):482-90.
39. Lederle FA, Johnson GR, Wilson SE, Gordon IL, Chute EP, Littooy FN, et al. Relationship of age, gender, race, and body size to infrarenal aortic diameter. *Journal of vascular surgery*. 1997;26(4):595-601.
40. Wolak A, Gransar H, Thomson LE, Friedman JD, Hachamovitch R, Gutstein A, et al. Aortic size assessment by noncontrast cardiac computed tomography: normal limits by age, gender, and body surface area. *JACC Cardiovasc. Imaging*. 2008;1(2):200-9.
41. Vaupel JW. How change in age-specific mortality affects life expectancy. *Population Studies*. 1986;40(1):147-57.
42. Romero-Ortuno R, Kenny RA. The frailty index in Europeans: association with age and mortality. *Age and ageing*. 2012;41(5):684-9.

Figure legends

Figure 1. Flowchart describing patient inclusion. Exact numbers for the respective cardiac measure specific populations are given in Supplementary table 1.

Figure 2. Average prognostic strength for predicting 5-year cardiovascular mortality when indexing for body size for right atrial area, right ventricular diameter, right ventricular outflow tract diameter, left atrial area, left ventricular diameter, left ventricular mass, and aortic sinus diameter. The axes represent the height and weight exponents of a body size indexation metric of the format $\text{height}^x * \text{weight}^y$. The color scale shows the prognostic strength from a C-statistic of 0.60 to 0.70, each increment representing a 1 %-point improvement. Existing body size metrics were plotted: h = height, w = weight, hw = height * weight, BMI = body mass index, BSA = body surface area, M = Mosteller, D = DuBois. In the normal weight/overweight group, from unindexed to body surface area by Mosteller there is a 4%-point improvement, but further improvement is limited to <1%-point. Similar trends can be observed in the underweight and obese group. See text for details.

	LV mass			LA area			RA area			Aortic sinus diameter			RV diameter			LV end-diastolic diameter			RVOT diameter			Average		
	BMI <18.5 kg/m ²	BMI 18.5-30 kg/m ²	BMI ≥30 kg/m ²	BMI <18.5 kg/m ²	BMI 18.5-30 kg/m ²	BMI ≥30 kg/m ²	BMI <18.5 kg/m ²	BMI 18.5-30 kg/m ²	BMI ≥30 kg/m ²	BMI <18.5 kg/m ²	BMI 18.5-30 kg/m ²	BMI ≥30 kg/m ²	BMI <18.5 kg/m ²	BMI 18.5-30 kg/m ²	BMI ≥30 kg/m ²	BMI <18.5 kg/m ²	BMI 18.5-30 kg/m ²	BMI ≥30 kg/m ²	BMI <18.5 kg/m ²	BMI 18.5-30 kg/m ²	BMI ≥30 kg/m ²	BMI <18.5 kg/m ²	BMI 18.5-30 kg/m ²	BMI ≥30 kg/m ²
Weight	0.697	0.723	0.664	0.734	0.705	0.626	0.704	0.668	0.591	0.640	0.645	0.562	-	0.652	0.656	-	0.611	0.583	-	0.652	0.656	0.646	0.665	0.620
Weight ^{1.5}	0.686	0.728	0.660	0.731	0.697	0.618	0.708	0.671	0.589	0.629	0.634	0.553	-	0.644	0.643	-	0.609	0.573	-	0.644	0.643	0.593	0.661	0.611
Height*Weight	0.701	0.728	0.670	0.731	0.703	0.627	0.705	0.672	0.593	0.627	0.637	0.564	-	0.650	0.652	-	0.611	0.582	-	0.650	0.652	0.643	0.664	0.620
BSA[Mosteller] ^{1.5}	0.707	0.722	0.670	0.732	0.706	0.631	0.702	0.669	0.593	0.635	0.645	0.571	-	0.654	0.659	-	0.611	0.590	-	0.654	0.659	0.649	0.666	0.625
BSA[Du Bois] ^{1.5}	0.711	0.721	0.671	0.732	0.706	0.633	0.701	0.669	0.594	0.633	0.644	0.574	-	0.653	0.660	-	0.610	0.592	-	0.653	0.660	0.650	0.665	0.626
BSA[Mosteller]	0.709	0.710	0.665	0.731	0.704	0.632	0.695	0.661	0.591	0.642	0.646	0.576	-	0.650	0.666	-	0.603	0.593	-	0.650	0.666	0.650	0.661	0.627
BSA[Du Bois]	0.712	0.709	0.666	0.731	0.703	0.633	0.695	0.661	0.592	0.641	0.645	0.579	-	0.650	0.668	-	0.602	0.596	-	0.650	0.668	0.652	0.660	0.629
LBM[Hume]	0.719	0.715	0.669	0.726	0.699	0.627	0.694	0.663	0.588	0.624	0.628	0.564	-	0.644	0.655	-	0.597	0.582	-	0.644	0.655	0.653	0.656	0.620
LBM[Boer]	0.719	0.712	0.662	0.727	0.693	0.616	0.695	0.659	0.579	0.626	0.617	0.543	-	0.636	0.636	-	0.588	0.562	-	0.636	0.636	0.653	0.649	0.605
LBM[James]	0.703	0.714	0.659	0.726	0.695	0.615	0.697	0.660	0.577	0.626	0.619	0.546	-	0.637	0.635	-	0.588	0.562	-	0.637	0.635	0.643	0.650	0.604
BMI	0.678	0.693	0.637	0.724	0.690	0.611	0.687	0.647	0.579	0.624	0.615	0.533	-	0.632	0.646	-	0.581	0.558	-	0.632	0.646	0.619	0.642	0.601
Height ^{2.7}	0.726	0.706	0.672	0.725	0.697	0.635	0.692	0.662	0.594	0.620	0.618	0.580	-	0.642	0.662	-	0.595	0.596	-	0.642	0.662	0.665	0.652	0.629
Height ^{2.13}	0.724	0.702	0.669	0.727	0.698	0.636	0.690	0.659	0.593	0.628	0.621	0.584	-	0.642	0.666	-	0.593	0.600	-	0.642	0.666	0.668	0.651	0.631
Height ²	0.724	0.701	0.668	0.727	0.697	0.636	0.690	0.658	0.593	0.630	0.621	0.585	-	0.642	0.667	-	0.592	0.600	-	0.642	0.667	0.668	0.650	0.631
Height ^{1.5}	0.720	0.695	0.663	0.727	0.695	0.635	0.687	0.653	0.591	0.635	0.618	0.585	-	0.640	0.669	-	0.586	0.599	-	0.640	0.669	0.667	0.647	0.630
Height	0.715	0.688	0.657	0.725	0.692	0.632	0.683	0.648	0.589	0.635	0.607	0.579	-	0.634	0.670	-	0.577	0.594	-	0.634	0.670	0.664	0.640	0.627
Unindexed	0.702	0.670	0.641	0.718	0.679	0.622	0.672	0.635	0.582	0.613	0.568	0.552	-	0.617	0.666	-	0.553	0.572	-	0.617	0.666	0.648	0.620	0.614

Table 1. C-statistic for 5-year cardiovascular mortality both unindexed and indexed by different body size metrics for representative anatomical measures, and their average. The underweight group for LV end-diastolic diameter, RV diameter and RVOT diameter have been removed due to unreliable C-statistics stemming from small sample sizes (n=1385, n=93 and n=38, respectively). BMI = body mass index, BSA = body surface area, LBM = lean body mass, RA = right atrial, RV = right ventricular, RVOT = right ventricular outflow tract, LA = left atrial, LV = left ventricular, IVS = interventricular septum.



